CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 380 enrolled
Drug / intervention
Bifidobacterium animalis subsp. lactis Bl-04 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02679807
NCT02679807N/ACompleted

Effect of Probiotic on Rhinovirus Induced Colds

University of Virginia·interventional·Posted Feb 10, 2016·Updated Mar 25, 2020

In Brief

A clinical study evaluating Bifidobacterium animalis subsp. lactis Bl-04 and sucrose for Common Cold. Completed, enrolled 380 participants.

Detailed Summary

This is a randomized, double-blind placebo controlled trial to evaluate the effect of a probiotic (Bl-04) on the occurrence of rhinovirus-associated common cold illness in the experimental rhinovirus challenge model. A previous study documented that Bl-04 has significant effects on the innate immune response in the nose and this study will be powered to assess whether these effects translate into a demonstrable clinical benefit. Volunteers will be given Bl-04 or placebo for 28 days then challenged with rhinovirus. The primary analysis will be on the proportion of volunteers who develop a rhinovirus associated illness in the two treatment groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
Countries--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 10, 2016
Enrollment StartFeb 1, 2016
Primary CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.4 years ago

Interventions

Bifidobacterium animalis subsp. lactis Bl-04biological

sucroseother